10-K: Sensei BioTherapeutics Focuses on Lead Candidate, Extends Cash Runway into Q2 2026

Sensei BioTherapeutics streamlines operations to prioritize clinical development of solnerstotug, extending its financial runway into the second quarter of 2026.

Summary

• Sensei BioTherapeutics is a clinical-stage biotechnology company concentrating on developing next-generation cancer therapeutics using its TMAb platform.
• The company's lead candidate, solnerstotug, is undergoing a Phase 1/2 clinical trial, with data from the dose expansion portion disclosed on March 27, 2025.
• Key findings from the dose expansion data include a 14% objective response rate and a 62% disease control rate among 21 evaluable PD-(L)1 resistant hot tumor patients.
• Subject to raising additional capital, Sensei plans to initiate a Phase 2 trial of solnerstotug in the first quarter of 2026.
• In November 2024, Sensei announced a restructuring to reduce operating expenses, including closing a research site and reducing the workforce by approximately 46%.
• The company expects its existing cash and cash equivalents to fund operating expenses and capital expenditure requirements into the second quarter of 2026.
• As of March 24, 2025, Sensei had 14 full-time employees and one part-time employee.
• The company's net loss for 2024 was $30.2 million, compared to $34.1 million in 2023.
• As of December 31, 2024, Sensei had cash, cash equivalents, and marketable securities totaling $41.3 million.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there are positive aspects such as promising clinical data for solnerstotug and plans for a Phase 2 trial, there are also negative aspects such as a history of net losses, a recent restructuring, and the need to raise additional capital. The overall sentiment is neutral, reflecting the challenges and opportunities facing the company.

Positives

• Solnerstotug shows promising clinical data in PD-(L)1 resistant hot tumor patients.
• The company is planning to initiate a Phase 2 trial of solnerstotug in Q1 2026.
• Restructuring efforts are expected to extend the company's cash runway into the second quarter of 2026.
• Solnerstotug continues to be well tolerated, with no dose-limiting toxicities and the majority of AEs Grade 1 or 2 in severity.

Negatives

• The company has a history of net losses and expects to continue incurring losses for the foreseeable future.
• Development of preclinical product candidates has been paused.
• Initiation of the Phase 2 trial of solnerstotug is contingent on raising additional capital.
• The company reduced its workforce by approximately 46%.

Risks

• The company's ability to continue operations is dependent on securing additional funding.
• Clinical trials may not demonstrate the safety and efficacy of product candidates.
• The company relies on third parties for manufacturing and clinical trials.
• The company faces significant competition in the biotechnology and pharmaceutical industries.
• The company may be unable to obtain and maintain patent protection for its technologies and product candidates.
• The company may be subject to legal proceedings alleging infringement of intellectual property rights.
• The company may experience difficulties in managing organizational growth.
• The company's future success depends on retaining key members of senior management and attracting qualified personnel.
• The trading price of the company's common stock may be volatile.
• The company may fail to maintain an effective system of internal control over financial reporting.

Future Outlook

Sensei plans to initiate a Phase 2 trial of solnerstotug in the first quarter of 2026, contingent on raising sufficient additional capital. The company expects its existing cash and cash equivalents to fund operating expenses and capital expenditure requirements into the second quarter of 2026.

Management Comments

• Management plans to continue reviewing financial resources with the expectation that work on preclinical product candidates will resume if sufficient additional capital is raised.

Industry Context

The biotechnology and pharmaceutical industries are highly competitive, with substantial investments in novel immunotherapies. Sensei faces competition from large pharmaceutical companies and other immuno-oncology companies developing similar therapies.

Comparison to Industry Standards

• The document mentions competitors such as AstraZeneca, Bristol Myers Squibb, Gilead Sciences, Merck, Novartis, Pfizer, Regeneron and Roche/Genentech, which are large pharmaceutical companies with significant resources in the immuno-oncology space.
• The document also mentions smaller immuno-oncology companies such as Hummingbird Bioscience, Kineta, PharmAbcine, Pierre Fabre and Curis, which are developing or have developed antibodies targeting VISTA, the target of Sensei's lead product candidate solnerstotug.
• The document does not provide specific comparisons of Sensei's results to industry benchmarks or comparable projects, but it does highlight the competitive landscape and the need for Sensei to differentiate its product candidates based on safety, efficacy, convenience, and treatment cost.

Related Party Transactions

• The company entered into a stock purchase agreement with Apeiron Investment Group to repurchase 4,454,248 shares of its common stock for $7.8 million.
• The company entered into a stock purchase agreement with Cambrian BioPharma, Inc. to repurchase 1,587,302 shares of its common stock for $2.0 million.

Stakeholder Impact

• Shareholders: Dilution may occur if additional equity is raised.
• Employees: Workforce reduction of approximately 46%.
• Patients: Potential for new cancer therapeutics through the development of solnerstotug.
• Suppliers: Potential changes in relationships due to restructuring.

Next Steps

• Continue clinical development of solnerstotug.
• Raise additional capital to fund operations and initiate a Phase 2 trial.
• Disclose updated clinical data from all evaluable patients by the end of 2025.
• Optimize the Phase 2 trial design based on ongoing dose expansion results.
• Pursue a reverse stock split in connection with the 2025 annual meeting of stockholders in order to regain compliance with the minimum bid price rule.

Key Dates

Keywords

solnerstotug, VISTA, TMAb platform, clinical trial, biotechnology, immuno-oncology, cancer therapy, Sensei Bio, SNSE, clinical development